Trial Profile

Phase II Study of Pembrolizumab in Combination With Radiation With or Without Olaparib in Localized High-risk Prostate Cancer

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 06 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Olaparib (Primary) ; Pembrolizumab (Primary) ; LHRH receptor agonists; LHRH receptor antagonists
Indications Adenocarcinoma; Prostate cancer
Focus Therapeutic Use

30 Jan 2026 Due to slow accrual and feasibility concerns, protocol was amended to a single-arm phase II study. All patients will receive definitive radiation therapy combined with androgen deprivation therapy (ADT) per institutional standards. Following Amendment 5, enrollment is limited to Arm 1 only, and Arm 2 (usual care) has been closed to accrual.
27 Jan 2024 Trial design presented at the 2024 Genitourinary Cancers Symposium
25 Jul 2023 Planned End Date changed from 2 Jul 2028 to 2 Jul 2029.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com